Design and synthesis of novel pegylated iron chelators with decreased metabolic rate.

Junpei Li, Zidong Lu, Xiaole Kong, Yongmin Ma, Xingyuan Zhang, Sukhvinder S Bansal, Vincenzo Abbate, Robert C Hider

Journal: Future medicinal chemistry 2016;7(18):2439-49

PMID: 26670054

Abstract

BACKGROUND

Deferiprone has proved to be a successful iron selective chelator in a range of pathologies. However, its use is limited by rapid Phase II metabolism, necessitating the administration of large doses. In an attempt to modify metabolic rate of this class of compounds, a range of pegylated 3-hydroxypyridin-4-ones has been synthesized.

EXPERIMENTAL

The synthetic route in which the polyethylene glycol counterparts are introduced to a protected pyran ring involves either a Williamson etherification reaction or direct addition leading to polyethylene glycol-containing precursors.

RESULTS & DISCUSSION

The introduction of the pegylated substituent was found to lead to a relatively low rate of metabolism for some of the derivatives (6a, 6b, 8a and 8b), offering a possible improvement over deferiprone.

Address: Department of Polymer Science & Engineering, University of Science & Technology of China, Hefei, Anhui 230026, China.; Institute of Pharmaceutical Science, King's College London, SE1 9NH London, UK.; College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, 310053 Hangzhou, China.

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.